About Exelixis
Exelixis (NASDAQ:EXEL), a biotechnology company, focuses on the discovery, development, and commercialization of new medicines for the treatment of cancer. They are known for their commitment to improving the outcomes for patients facing cancer challenges through the development of innovative therapies. The company's projects span across a range of oncology indications, aiming to address unmet medical needs and enhance the effectiveness of cancer care. At the heart of Exelixis's objectives is the ambition to leverage scientific breakthroughs and advanced technologies to create a robust pipeline of therapeutic candidates, with the ultimate goal of transforming the landscape of cancer treatment and bringing hope to patients and their families.
Snapshot
Operations
Products and/or services of Exelixis
- CABOMETYX (cabozantinib), a treatment for various forms of cancer including renal cell carcinoma and hepatocellular carcinoma.
- COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer.
- Collaboration with Bristol Myers Squibb to develop novel therapies for cancer employing a combination of therapies including cabozantinib.
- Partnership with Ipsen for the co-development and commercialization of cabozantinib for oncology outside the U.S.
- Agreement with Takeda to co-develop and commercialize cabozantinib for all future indications in Japan.
- Research and development program focused on the discovery of new compounds targeting receptor tyrosine kinases for the treatment of cancer.
Exelixis executive team
- Dr. Stelios Papadopoulos Ph.D.Co-Founder & Independent Chair of the Board
- Dr. Michael M. Morrissey Ph.D.CEO, President & Director
- Mr. Christopher J. SennerExecutive VP & CFO
- Dr. Dana T. Aftab Ph.D.Executive Vice President of Research & Development
- Ms. Susan T. HubbardExecutive Vice President of Public Affairs & Investor Relations
- Dr. Brenda Hefti J.D., Ph.D.Senior VP & General Counsel
- Dr. Anne Champsaur M.D.Senior Vice President of Drug Safety
- Dr. William Berg M.D.Senior Vice President of Medical Affairs
- Mr. Patrick Joseph Haley M.B.A.Executive Vice President of Commercial
- Dr. Stefan Krauss Ph.D.VP & Head of Business Development